Financials data is unavailable for this security.
View more
Year on year Marksans Pharma Ltd grew revenues 17.56% from 18.52bn to 21.77bn while net income improved 17.80% from 2.66bn to 3.14bn.
| Gross margin | 53.39% |
|---|---|
| Net profit margin | 14.71% |
| Operating margin | 17.81% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in INRView more
In 2024, Marksans Pharma Ltd increased its cash reserves by 5.45%, or 208.40m. The company earned 2.30bn from its operations for a Cash Flow Margin of 10.58%. In addition the company used 1.41bn on investing activities and also paid 687.27m in financing cash flows.
| Cash flow per share | 9.16 |
|---|---|
| Price/Cash flow per share | 32.73 |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
Growth rates in INR
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 20.00% and 7.98%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked above the industry average relative to its peers.
| Div yield(5 year avg) | 0.51% |
|---|---|
| Div growth rate (5 year) | 64.38% |
| Payout ratio (TTM) | 6.79% |
| EPS growth(5 years) | 29.95 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 14.33 |
More ▼
